P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES. (23rd June 2022)

• Record Type: Journal Article
• Authors: Vassilakopoulos, T.; Ferhanoglu, B.; Horowitz, N. A.; Apostolidis, J.; Mellios, Z.; Kaynar, L.; Zektser, M.; Symeonidis, A.; Piperidou, A.; Kalpadaki, C.; Akay, O. M.; Atalar, S. C.; Sayyed, A.; Katodritou, E.; Leonidopoulou, T.; Papageorgiou, S.; Tadmor, T.; Gutwein, O.; Karakatsanis, S.; Ganzel, C.; Karianakis, G.; Isenberg, G.; Gainaru, G.; Vrakidou, E.; Palassopoulou, M.; Ozgur, M.; Siakantaris, M.; Paydas, S.; Tsirigotis, P.; Tsirogianni, M.; Hatzimichael, E.; Tuglular, T. F.; Chatzidimitriou, C.; Liaskas, A.; Lefaki, M. A.; Kanellias, N.; Zikos, P.; Koumarianou, A.; Gafter-Gvili, A.; Angelopoulou, M.; Karmiris, T.; Gurion, R.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 1114
• Page End: 1115
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000847780.61937.3d
• Languages: English
• ISSNs: 2572-9241